FLII and sarcoma: These efforts have been successful, yielding potentiated variants that robustly suppress the toxicity and mislocalization of proteins including TDP-43 (TAR DNA-binding protein 43) and FUS (fused in sarcoma) (implicated in ALS), α-synuclein (implicated in PD), as well as FUS-CHOP (CCAAT-enhancer-binding protein (C/EBP) homologous protein) and EWS-FLI (Ewing sarcoma-friend leukemia integration 1 transcription factor) (implicated in sarcoma)[17, 18, 24, 25].